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Abstract
Opioid users experience increased incidence of infection, which may be partially attributable to 
both direct opiate-immune interactions and conditioned immune responses. Previous studies have 
investigated the neural circuitry governing opioid conditioned immune responses, but work 
remains to elucidate the mechanisms mediating this effect. Our laboratory has previously shown 
that hippocampal IL-1 signaling, specifically, is required for the expression of heroin conditioned 
immunosuppression following learning. The current studies were designed to further characterize 
the role of hippocampal IL-1 in this phenomenon by manipulating IL-1 during learning. 
Experiment 1 tested whether hippocampal IL-1 is also required for the acquisition of heroin 
conditioned immunosuppression, while Experiment 2 tested whether hippocampal IL-1 is required 
for the expression of unconditioned heroin immunosuppression. We found that blocking IL-1 
signaling in the dorsal hippocampus with IL-1RA during each conditioning session, but not on 
interspersed non-conditioning days, significantly attenuated the acquisition of heroin conditioned 
immunosuppression. Strikingly, we found that the same IL-1RA treatment did not alter 
unconditioned immunosuppression to a single dose of heroin. Thus, IL-1 signaling is not a critical 
component of the response to heroin but rather may play a role in the formation of the association 
between heroin and the context. Collectively, these studies suggest that IL-1 signaling, in addition 
to being involved in the expression of a heroin conditioned immune response, is also involved in 
the acquisition of this effect. Importantly, this effect is likely not due to blocking the response to 
the unconditioned stimulus since IL-1RA did not affect heroin’s immunosuppressive effects.
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 1. Introduction
Opioid users show an increased incidence of infections (Govitrapong et al., 1998; Louria et 
al., 1967; Risdahl et al., 1998), the treatment of which imposes a large economic burden 
(Mark et al., 2001). These infections are not simply due to increased pathogen exposure 
from intravenous drug use, but may also be attributed to opiates’ interaction with the 
immune system (Horsburgh et al., 1989; Simonovska et al., 2011; Vallejo et al., 2004). 
Furthermore, while opioids on their own hinder the body’s ability to respond to disease and 
infection, these immunosuppressive properties can become conditioned. Repeated 
presentations of immune modulators, like opioids, with predictive stimuli can result in 
Pavlovian conditioning of immune system function, allowing for these stimuli to later affect 
the immune system in the same way as the modulators themselves [for review (Schedlowski 
and Pacheco-Lopez, 2010)]. Therefore, exposure to opioid-associated environments or 
stimuli might then lead to an exacerbation of immunological vulnerability in opioid users.
Conditioned immune responses have been demonstrated in rodent models using stimuli 
paired with distinct immunosuppressive agents such as cyclophosphamide (Ader, 1974; 
Ader and Cohen, 1975), cyclosporine A (Exton et al., 2001; Exton et al., 1998a; Exton et al., 
1998b; von Horsten et al., 1998), foot shock stress (Lysle et al., 1988; Perez and Lysle, 
1995), cocaine (Kubera et al., 2008), morphine (Coussons-Read et al., 1994a, b; Coussons et 
al., 1992; Luecken and Lysle, 1992), and heroin (Lysle and Ijames, 2002; Szczytkowski et 
al., 2011; Szczytkowski and Lysle, 2007, 2008, 2010). Heroin conditioned immune effects 
are of particular concern due to recent rises in heroin’s use (United States. Substance Abuse 
and Mental Health Services Administration, 2014). The NIH attributes this rise to the near 
tripling of opioid prescriptions in order to treat pain in the last decade that may have led 
many to turn to heroin as a cheaper alternative to costly pain medication (United States. 
National Institute on Drug Abuse, 2014). With opioid use, including heroin, on the rise, it 
becomes more important than ever to understand the immune consequences of their use and 
the neural mechanisms governing the classical conditioning that may increase the severity or 
duration of these consequences.
Like other forms of immune conditioning, which have been primarily studied within the 
context of placebo effects [for review (Schedlowski et al., 2015)], opioid immune 
conditioning is centrally mediated (Fecho et al., 1996; Lysle et al., 1996) and depends on 
learned associations between a conditioned stimulus (CS) and opioids, as unconditioned 
stimuli (US). After multiple pairings of the CS and the US, the CS itself becomes able to 
evoke a conditioned response (CR) similar to the effects of opioids themselves (Lysle and 
Ijames, 2002). For example, a single injection of heroin has been shown to suppress 
measures of nitric oxide (NO) (Lysle and How, 2000), an important part of the immune 
system released by multiple immune cells that conveys resistance to infection and serves as a 
regulator of immune function (Bogdan, 2001; Lewis et al., 2010; MacMicking et al., 1995; 
Nathan and Shiloh, 2000; Uehara et al., 2015). Its expression is potently and widely induced 
by lipopolysaccharide (LPS), a component of gram negative bacterial walls. NO production 
can be indirectly measured by levels of inducible nitric oxide (iNOS), the enzyme 
responsible for producing NO, and nitrate/nitrite, byproducts of NO degradation in the 
blood.
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Previous studies have taken advantage of LPS’s potent induction of NO to investigate 
heroin’s immune effects (Lysle and How, 2000). The effects of heroin on LPS-induced NO 
are also able to be conditioned to heroin-associated stimuli. Pairing heroin (US) with a 
distinct environmental context (CS) allows the heroin-paired context to evoke a CR in rats in 
that the exposure to the context alone will cause conditioned suppression of NO (Lysle and 
Ijames, 2002; Szczytkowski et al., 2011; Szczytkowski et al., 2013; Szczytkowski and Lysle, 
2007, 2008, 2010). Research using this model has demonstrated that the basolateral 
amygdala, nucleus accumbens (Saurer et al., 2009; Szczytkowski and Lysle, 2008), and a 
circuit comprised of these regions and the ventral tegmental area is necessary for the 
expression of heroin conditioned immunosuppression (Szczytkowski et al., 2011). More 
recently, the hippocampus, a brain region heavily implicated in contextual learning (Maren 
and Holt, 1999; Phillips and Ledoux, 1994; Redish, 2001) has also been shown to be 
involved in the expression of heroin conditioned immunosuppression. Inactivation of the 
dorsal hippocampus (DH) using a GABA agonist cocktail, baclofen/muscimol, or 
knockdown of interleukin-1β (IL-1β) signaling within the DH just before testing prevented a 
heroin-paired context from suppressing the immune response to LPS (Szczytkowski et al., 
2013). This not only suggests the requirement of the DH for the expression of heroin 
conditioned immunosuppression, but also implicates a novel role for brain IL-1β in this 
effect.
IL-1β is a pro-inflammatory cytokine that has been linked to learning and memory. Studies 
suggest this cytokine is induced in the DH by Pavlovian conditioning (Goshen et al., 2007), 
is required for the maintenance of long-term potentiation (LTP) (Schneider et al., 1998), and 
causes disruption of normal memory at either supra- or sub-optimal expression levels (Avital 
et al., 2003; Ben Menachem-Zidon et al., 2011; Goshen et al., 2007; Griffin et al., 1989; 
Ross et al., 2003; Schmid et al., 2009; Schneider et al., 1998). Furthermore, IL-1 seems to 
play a key role in memory within the hippocampus as IL-1 manipulations specifically affect 
hippocampal-dependent memory but not hippocampal-independent memory [for review 
(Lynch, 2015)], and levels of IL-1 receptor in the hippocampus are particularly high [see 
(Schneider et al., 1998)].
Given that IL-1 in the hippocampus is important for the expression of heroin conditioned 
immunosuppression, it is yet to be determined if hippocampal IL-1 is also required for the 
encoding of immune associations during acquisition. Therefore, in the present studies, 
Experiment 1 sought to investigate whether hippocampal blockade of the most well-studied 
receptor for IL-1, IL-1 receptor 1 (IL-1R1), could interfere with the acquisition of heroin 
conditioned immunosuppression.
Many studies suggest that the CR is specific to and mimics the effects of the US [see 
(Schedlowski et al., 2015)], which may suggest that the neural pathways engaged during the 
expression of a CR recapitulate those engaged by the US. In the context of our model, it is 
unknown whether IL-1 signaling is required for heroin’s immunosuppressive effects. If IL-1 
in the dorsal hippocampus is specifically required for memory processes engaged in 
connecting the immune effects of the US to the CS, then blockade of IL-1 signaling in the 
dorsal hippocampus will not interfere with the immunosuppressive response to a heroin US. 
Experiment 2 investigated the possibility that IL-1 in the dorsal hippocampus has a 
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distinguishable role in associative learning and not in mediating the unconditioned response 
to the US.
The present studies will critically inform our understanding of how stimuli-drug associations 
engage memory and immune systems, possibly providing therapeutic targets to aid in the 
prevention of the negative health consequences associated with opioid use.
 2. Methods and Materials
 2.1 Animals
Adult, male Lewis rats (N = 55) weighing 225-250 g were purchased from Charles-River 
Laboratories (Raleigh, NC). Animals were housed individually in a colony room under a 
reversed 12-hour day-night cycle, with ad libitum access to food and water. Animals 
received at least 12 days of habituation before experimentation and were handled regularly 
during this time. All procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of North Carolina at Chapel Hill and conformed to 
the National Research Council’s Guide for the Care and Use of Laboratory Animals 
(Institute for Laboratory Animal Research Division of Earth and Life Studies).
 2.2 Drugs & Delivery
Heroin (diacetylmorphine) was obtained from NIDA’s Drug Supply System (Bethesda, MD) 
and was dissolved in 0.9 % sterile saline to a final concentration of 1.0 mg/mL. Throughout 
conditioning, heroin solutions were stored at 4°C. Heroin-filled syringes were allowed to 
come to room temperature prior to injections. Rats were injected subcutaneously with 1.0 
mg/kg heroin, a dose chosen based on prior experiments in our laboratory showing that this 
dosage alters LPS-induced iNOS mRNA expression in the spleen (Lysle and How, 2000, 
Lysle and Ijames, 2002, Szczytkowski and Lysle, 2007). Lipopolysaccharide (LPS) was 
injected subcutaneously at a concentration of 1 mg/kg (derived from E. coli, serotype 
055:B5, dissolved in sterile, pyrogen-free saline), a dose which induces sickness behavior 
and produces reliable induction of nitric oxide measures. This particular serotype has been 
used previously in our laboratory to investigate immune responses following heroin 
conditioning, an important verification due to the differing activity between LPS serotypes 
even from within the same species (Caroff et al., 2002). Human recombinant interleukin-1 
receptor antagonist (IL-1RA) (Genscript, Piscataway, NJ, Catalog No: Z00367) was 
reconstituted in 0.9% sterile saline to a final concentration of 2.5 μg/μL. Reconstituted 
IL-1RA was then aliquoted and stored at −20°C. Rats were intracranially infused with 1.25 
μg in 0.5 μL volume per hemisphere into the dorsal hippocampus (DH) over 2 minutes at a 
constant rate of 0.25 μL/min. Thereafter, the injectors were allowed to sit for 1 additional 
minute to allow for proper diffusion from the injection site. At least 48 hours prior to 
intracranial drug infusion into the DH, injectors were lowered into the cannulae and the rats 
were handled to habituate them to the infusion procedures. Just prior to infusion, frozen 
IL-1RA aliquots were thawed on ice, briefly centrifuged, and stored on ice throughout. 
Vehicle infusions were of 0.9% sterile saline.
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 2.3 Surgical Procedure
Animals were anesthetized with 1.0 mL/kg intraperitoneally injected 9:1 (vol:vol) ketamine 
hydrochloride (100 mg/mL) and xylazine (100 mg/mL). Surgically prepared animals were 
placed into the stereotaxic apparatus where guide cannula (26-gauge, Plastics One, Roanoke, 
VA) were directed bilaterally toward the DH with coordinates AP −3.4 mm, ML ±3.1 mm, 
DV −2.2 mm, relative to bregma; 15° angle laterally (Paxinos and Watson, 1998). Animals 
were given at least 13 days for post-operative recovery during which they were handled and 
monitored regularly.
 2.4 Conditioning Procedure
Rats received five, 60-min conditioning sessions every other day as in prior studies, which 
has been shown to be sufficient to generate conditioned immunosuppression to the heroin-
paired context (Szczytkowski et al., 2011; Szczytkowski et al., 2013; Szczytkowski and 
Lysle, 2010). Each conditioning session involved heroin administration (US) immediately 
followed by placement into a conditioning chamber (BRS/LVE, Laurel, MD, USA; W 30.5 
cm × D 24.1 cm × H 26.7 cm) that served as the conditioned stimulus (CS). The 
conditioning chambers were contained within closable sound and light attenuating chambers 
(W 50.8 cm × D 34.3 cm × H 36.8 cm) with house fans, located in a room separate from the 
animal colony. The conditioning chambers contained a standard footshock metal bar floor, 
two clear plastic front and black walls, a clear plastic ceiling, and two metal side walls. 
Below the bar floor, a floor tray containing cedar bedding was inserted to enhance the 
distinction of the conditioning environment from the home cage. In between animals, 
chambers were thoroughly cleaned using Roccal-D Plus disinfectant (Zoetis, Kalamazoo, 
MI).
Prior work in our laboratory has shown that unmanipulated animals, saline conditioned 
animals, or animals that received the CS and US in an unpaired manner do not demonstrate 
context-induced immunosuppression. This indicates that immunosuppression is specifically 
due to re-exposure to a heroin-paired CS and not ancillary effects of conditioning, receiving 
heroin, or injections in general (Lysle and Ijames, 2002).
 2.5 Tissue Collection
Immediately after the 60-min test session (or home cage exposure for controls), rats were 
injected with LPS. Rats were sacrificed and tissue was collected 6 hours after LPS injection. 
The spleen was analyzed because immunohistochemical localization of iNOS in rats 
exposed to LPS shows the presence of the iNOS enzyme in a number of immune cells found 
in the spleen, including macrophages, lymphocytes, and neutrophils (Bandaletova et al., 
1993). Following sacrifice, spleen was dissected out and cut into approximately 100 mg 
sized pieces for RT-qPCR and ELISA. Tissue was placed in cOmplete Protease Inhibitor 
Cocktail (Roche Diagnostics, Indianapolis, IN) and stored at −80°C.
 2.6 RNA Extraction & RT-qPCR
To determine iNOS mRNA expression, reverse transcription quantitative real-time PCR (RT-
qPCR) was performed on spleen tissue samples. Collected tissue was processed by the UNC 
Animal Clinical Chemistry and Gene Expression Laboratories according to previous 
Lebonville et al. Page 5
Brain Behav Immun. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
protocols (Kim et al., 2002). Briefly, tissue was homogenized in RNA lysis buffer (PE 
Biosystems, Foster City, CA) with Ca2+ and Mg2- free PB using a Fast Prep 120 mixer 
(QBIOgene, Vista, CA). RNA was purified using an automated nucleic-acid workstation 
(ABI Prism 6700, PE Biosystems) according to the manufacturer’s protocol. The amount of 
RNA used in the RT-qPCR reaction (one-step) was equalized between samples. RT-qPCR 
reactions were performed in a sequence detector (ABI Prism 7700, PE Biosystems) in a total 
volume of 30 μL (10 μL RNA, 20 μL reaction cocktail). Each RT-qPCR amplification was 
performed in duplicate under the following reaction conditions: 30 min at 48°C for the RT 
reaction, 10 min at 94°C, and then 40 cycles of 15s at 94°C and 1 min at 60°C. Raw results 
were normalized to reference gene 18S to control for small variations in the amount of 
starting cDNA template. The stability of 18S as a reference gene was verified using a 2×2 
ANOVA to demonstrate that there were no significant group differences in 18S expression. 
Normalized values were then calibrated against either a global normalized average Ct value 
(Experiment 1) or a control group normalized average Ct (Experiment 2) for the gene of 
interest. For graphical representation, delta delta Ct values were linearly transformed. The 
nucleotide sequences of the qPCR primers and fluorogenic probes used for iNOS and 18S 
were as follows - iNOS forward: 5’-AGCGGCTCCATGACTCTCA-3’, reverse: 5’-
TGCCTGCACCCAAACACCAA-3’, probe: 5’-
FTCATGCGGCCTCCTTTGAGCCCTCQ-3’; 18S forward: 5’-
AGAAACGGCTACCACATCCA-3’, reverse: 5’-CTCGAAAGAGTCCTGTATTGT-3’, 
probe: 5’-FAGGCAGCAGGCGCGCAAATTACQ-3’ [F = 5’- Fluorescein (FAM); Q = 
Quencher (TAMRA)].
 2.7 Protein Extraction/Quantification & iNOS ELISA
Spleen tissue was homogenized on ice in sterile Dounce grinders. Protein was extracted 
from homogenized samples using cycles of freeze-thaw lysis, centrifugation, and collection 
of the supernatant. Total protein was quantified by Bradford Assay. Briefly, 10 μL of 1:200 
diluted protein, in triplicate, was incubated with 200 μL diluted and filtered Bradford Assay 
Dye (Bio-Rad Laboratories Inc., Hercules, CA, Catalog No. 500-0006) for 10 min. The 
absorbance of each sample triplicate was measured in a spectrophotometer (Epoch™, BioTek 
Instruments Inc., Winooski, VT) at 595 nm, averaged, and compared to a concurrently run 
BSA standard curve to determine μg/μL concentration. Splenic iNOS protein was quantified 
using a rat iNOS sandwich ELISA kit (LifeSpan BioSciences, Inc., Seattle, WA, Catalog No. 
LS-F4109). The user manual supplied with the kit was followed with the following 
parameters: 200 μg of total protein per sample was loaded in duplicate, plates were gently 
agitated at 45-55 rpm, and color was allowed to develop for 20-25 min. The ELISA plate 
was washed with an automatic plate washer (EL 403, BioTek Instruments Inc., Winooski, 
VT) as recommended by the kit manual. Each plate was read in a spectrophotometer at 450 
nm and compared to a concurrently run standard curve to determine pg iNOS protein per 
200 μg of total protein.
 2.8 Nitrate/Nitrite Assay
The nitrate/nitrite concentration in plasma samples was assessed using the Greiss reagent 
assay as described previously (Szczytkowski and Lysle, 2007). Briefly, 12 μL of plasma 
diluted in 38 μL of dH2O was incubated in the dark for 90 min with 10 μL of nitrate 
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reductase (1.0 U/mL), 20 μL of 0.31 M phosphate buffer (pH 7.5), 10 μL of 0.86 mM beta-
nicotinamide adenine dinucleotide phosphate reduced tetrasodium salt (NADPH, Sigma-
Aldrich Inc., Milwaukee, WI), and 10 μL of 0.11 mM flavin adenine dinucleotide in 
individual wells of a 96-well plate. Then, 200 mL of Greiss reagent, consisting of a 1:1 (v/v) 
solution 1% sulfanilamide in 5.0% phosphoric acid and 0.1% N-(1-
Naphthyl)ethylenediamine dihydrochloride (Kodak) in distilled water, was added to the 
samples. The color developed for 10 min at room temperature, after which, absorbance at 
550 nm was determined using a spectrophotometer. All reactions were carried out in 
triplicate. The total micromolar concentration of nitrite was determined for each sample 
based on a concurrently produced standard curve. Recovery of nitrate is greater than 95% 
using this assay.
 2.9 Histology
To confirm proper cannula placement, Alcian blue dye was infused via the cannulae 
following euthanasia. For Experiment 1, brains were extracted and immediately flash frozen 
in a low temperature freezing bath (Histobath NesLab, Portsmouth, NH; Shandon Lipshaw, 
Pittsburgh, PA) with freezing-cold isopentane, wrapped in aluminum foil, and stored at 
−80°C. For Experiment 2, brains were extracted and post-fixed at 4°C for 5 days in 4% 
paraformaldehyde. Following fixation, the brains were transferred to 30% sucrose solution 
for three days for cryoprotection. Brains were then frozen in a low temperature freezing bath 
(Histobath NesLab, Portsmouth, NH; Shandon Lipshaw, Pittsburgh, PA) with freezing-cold 
isopentane, wrapped in aluminum foil, and stored at −80°C. For both experiments, 40 μm 
coronal sections were collected using a freezing microtome (Leica CM 3050 S, Leica-
Microsystems, Germany) and allowed to dry on the slide for 30 min at room temperature 
before analysis. Cannula tracts were identified under a light microscope and the most ventral 
point of each tract was documented on rat brain atlas figures. Subjects with incorrect 
placement of cannula were removed from all analyses. Sections were stained with thionin 
and coverslipped for long-term storage.
 2.10 Statistical Analysis
A 2×2 analysis of variance (ANOVA) was performed on data sets using SPSS Statistics 
(IBM, Armonk, NY), after verifying that the underlying assumptions of the test were met. 
Homogeneity of variance was tested using Levene’s Test and normality using Shapiro-Wilk 
Test. For all tests, the significance level was set at 0.05. Tukey’s Honestly Significant 
Difference (HSD) post-hoc test was then used to detect either differences between CS-
exposed and corresponding home cage control groups (Experiment 1) or differences between 
heroin-injected vs. saline-injected groups and the effect of pre-treatment with IL-1RA vs. 
saline within heroin-injected groups (Experiment 2). For RT-qPCR, statistics were run on 
delta delta Ct values and not the linear transform because the former demonstrated 
normality.
 2.11 Experiment Specific Procedures
 2.11.1 Experiment 1: IL-1RA Antagonism During Acquisition of Heroin 
Conditioned Immunosuppression—For Experiment 1, animals (N = 31) were 
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repeatedly microinjected with IL-1RA into the DH at two time points relative to 
conditioning. One group (IL-1RA With Cond; n = 16) received IL-1RA 30 minutes prior to 
receiving heroin and being placed into the conditioning chamber to test whether DH IL-1 
signaling during conditioning is required for acquisition of heroin conditioned 
immunosuppression. Another group (IL-1RA 24 h After Cond; n = 15) received IL-1RA 24 
hours after conditioning, on the days in between conditioning sessions (non-conditioning 
days), to test whether IL-1 signaling is specifically required during conditioning sessions for 
acquisition. For both groups, infusions were given on both conditioning and non-
conditioning days and vehicle infusions were given at times when animals were not 
administered IL-1RA (Figure 1). This design ensured that all animals received injections 
before conditioning and that all animals received the same total number of IL-1RA 
infusions. This meant that differences between groups would not reflect ancillary effects of 
infusion timing relative to conditioning nor possible non-specific compensatory effects from 
receiving multiple IL-1RA injections. IL-1RA has a short half-life when injected 
systemically (21-108 minutes) (Granowitz et al., 1992). Unfortunately there is no data 
confirming the timeline of IL-1RA clearance from brain tissue. However, studies 
investigating effects of intracerebroventricular or hippocampal infusion of IL-1RA have 
shown that IL-1RA effects may last on the order of hours (Schmid et al., 2009; Schneider et 
al., 1998). This evidence suggests that separating IL-1RA treatment regimens by a full day, 
as in the current study, will likely limit temporal overlap of IL-1RA action between groups.
Six days after the last infusion (seven from the last conditioning session), half of the rats 
from each group were tested for expression of conditioned immunosuppression by being re-
exposed to the conditioning chamber (CS) for a single 60-min session, while the other half 
were not re-exposed and instead remained in their home cages (HC) for 60 min. Thus, 
conditioning in the latter group of home-cage controls was not evoked and this group was 
used for baseline comparison within each treatment regimen. Immediately thereafter, all rats 
received a single subcutaneous injection of LPS to induce in vivo production of nitric oxide. 
Rats were sacrificed 6 hours after LPS injection by cervical dislocation and a sample of 
spleen and blood were obtained for the analysis of iNOS mRNA, iNOS protein, and nitrate/
nitrite.
 2.11.2 Experiment 2: IL-1RA Antagonism During Heroin Unconditioned 
Immunosuppression—For Experiment 2, animals (N = 24) received a DH infusion of 
either IL-1RA or vehicle 30 min before a single subcutaneous heroin or saline injection 
(Figure 3). In order to mirror the time point of Experiment 1, animals were returned to their 
home cage for an hour, the length of Experiment 1 conditioning sessions, and were then 
injected a single time subcutaneously with LPS to induce in vivo production of nitric oxide. 
Six hours after LPS injection, rats were sacrificed by cervical dislocation and a sample of 
spleen and blood were obtained for the analysis of iNOS mRNA, iNOS protein, and nitrate/
nitrite.
 3. Results
Experiment 1 investigated the effects of DH IL-1 signaling blockade on the acquisition of 
heroin conditioned immunosuppression by injecting IL-1RA into the DH either during each 
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conditioning session or 24 hours after each conditioning session, on non-conditioning days. 
In the final analyses, group sizes were n = 8 for IL-1RA With Cond - HC, IL-1RA With 
Cond - CS, and IL-1RA 24 h After Cond - CS groups. For the IL-1RA 24 h After Cond - HC 
group, n = 7 for nitrate/nitrate and iNOS protein analyses and n = 6 for iNOS mRNA 
analyses. One subject was removed from iNOS mRNA analysis due to outlying 
housekeeping data that signified a problem with RNA extraction/cDNA synthesis.
A 2×2 ANOVA revealed significant differences between groups for splenic iNOS mRNA 
(F(3,26) = 13.857, p < 0.001, Figure 2A). There were significant main effects of drug timing 
(F(1,26) = 11.387, p < 0.01) and exposure treatment (F(1,26) = 23.836, p < 0.001) on iNOS 
mRNA. Post-hoc analysis, using Tukey’s HSD, revealed that iNOS mRNA was statistically 
significantly reduced in animals that were re-exposed to the CS and received IL-1RA 24 h 
after conditioning (IL-1RA 24 h After Cond – CS), compared to the corresponding home 
cage control group that was not re-exposed but received the same treatment regimen 
(IL-1RA 24 h After Cond – HC, p < 0.001). No statistically significant suppression of iNOS 
mRNA was seen in animals re-exposed to the CS that received IL-1RA treatment just before 
each conditioning session (IL-1RA With Cond – CS), compared to the corresponding home 
cage control group that was not re-exposed (IL-1RA With Cond – HC, p > 0.17), indicating 
that DH IL-1RA blocked the acquisition of heroin conditioned suppression of iNOS mRNA 
when administered just before, but not 24 h after, conditioning sessions.
A 2×2 ANOVA revealed significant differences between groups for splenic iNOS protein as 
well (F(3,27) = 6.073, p < 0.01, Figure 2B). There were significant main effects of drug 
timing (F(1,27) = 5.244, p < 0.04) and exposure treatment (F(1,27) = 8.83, p < 0.01) on iNOS 
protein. Post-hoc analysis, using Tukey’s HSD, revealed that, like with iNOS mRNA, iNOS 
protein was statistically significantly reduced in animals that received DH IL-1RA 24 h after 
conditioning, on non-conditioning days, and were re-exposed to the CS (IL-1RA 24 h After 
Cond – CS) compared to the corresponding home cage control group that was not re-
exposed but received the same treatment regimen (IL-1RA 24 h After Cond – HC, p < 0.02). 
No statistically significant suppression of iNOS protein was seen in animals that received 
IL-1RA treatment just before each conditioning session (IL-1RA With Cond – CS) 
compared to the corresponding home cage control group that was not re-exposed (IL-1RA 
With Cond – HC, p > 0.87). These results demonstrate that IL-1RA administration into the 
DH during conditioning, but not 24 h later, disrupts the acquisition of heroin conditioned 
suppression of iNOS protein.
A 2×2 ANOVA revealed significant differences between groups for plasma nitrate/nitrite as 
well (F(3,27) = 7.518, p < 0.01, Figure 2C). There were significant main effects of drug 
timing (F(1,27) = 6.810, p < 0.02) and exposure treatment (F(1,27) = 14.387, p < 0.01) on 
plasma nitrate/nitrite. Post-hoc analysis, using Tukey’s HSD, revealed that nitrate/nitrite was 
statistically significantly reduced in animals that received IL-1RA 24 h later on non-
conditioning days when re-exposed to the CS (IL-1RA 24 h After Cond - CS) in comparison 
to the corresponding home cage control group that was not re-exposed (IL-1RA 24 h After 
Cond - HC, p < 0.02). No statistically significant suppression of nitrate/nitrite upon re-
exposure to the CS was seen in animals that received IL-1RA treatment just before each 
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conditioning session (IL-1RA With Cond - CS) compared to the corresponding home cage 
control group that was not re-exposed (IL-1RA With Cond - HC, p > 0.17).
Thus, we observed significant attenuation of heroin conditioned immunosuppression when 
IL-1RA was infused into the DH just before, but not 24 h after, each conditioning session in 
both iNOS mRNA and protein and in plasma nitrate/nitrite. This indicates that IL-1 
signaling blockade in the DH during conditioning sessions blocks acquisition of heroin 
conditioned immunosuppression.
Experiment 2 investigated the effects of DH IL-1 signaling blockade on heroin 
unconditioned immunosuppression. In the final analyses, group sizes were n = 6 for the 
Sal/Sal group, n = 7 for Sal/Her and IL-1RA/Sal groups, and n = 4 for the IL-1RA/Sal 
group. Three subjects were removed from analysis due to incorrect cannula placement.
A 2×2 ANOVA revealed a significant difference between treatment groups (iNOS mRNA: 
F(3,20) = 9.604, p < 0.001, Figure 4A; iNOS protein: F(3,20) = 16.007, p < 0.001, Figure 4B; 
nitrate/nitrite: F(3,20) = 13.934, p < 0.001, Figure 4C). There was a significant main effect of 
heroin treatment for iNOS mRNA (F(1,20) = 26.050, p < 0.001), iNOS protein (F(1,20) = 
46.741, p < 0.001), and plasma nitrate/nitrite (F(1,20) = 40.728, p < 0.001). There was no 
main effect of IL-1RA treatment for iNOS mRNA, iNOS protein, or nitrate/nitrite (p > 0.4 
for all measures). Post-hoc analysis, using Tukey’s HSD, revealed that heroin-injected 
groups showed significantly decreased immune activation compared to saline-injected 
control groups (iNOS mRNA: p < 0.05; iNOS protein: p < 0.006; nitrate/nitrite: p < 0.01), 
but there was no effect of IL-1RA treatment on heroin suppression of these measures to 
immune challenge (iNOS mRNA: p > 0.38; iNOS protein: p > 0.68; nitrate/nitrite: p > 0.74). 
This indicates that IL-1RA in the DH does not block unconditioned immunosuppression by 
a single heroin injection. It is possible, however, that over repeated treatments of heroin and 
IL-1RA, as in the dosing regimen used in Experiment 1, that effects of IL-1RA on heroin 
immunosuppression would begin to arise.
 4. Discussion
Heroin-paired contexts gain the ability to suppress the immune system, like heroin itself, 
through conditioning. This effect could contribute to the increased risk of infection seen in 
heroin users. Evidence suggests that the cytokine interleukin-1β (IL-1β) is required at 
physiological levels to support learning and memory. We demonstrate here that preventing 
IL-1 signaling centrally in the dorsal hippocampus (DH) during each conditioning session in 
the acquisition phase, a time when heroin and a context can become associated, prevents the 
heroin-paired context from suppressing the immune system during a subsequent expression 
test. This effect was not seen if IL-1 signaling was blocked in the DH between conditioning 
sessions on non-conditioning days. Subsequently, we tested whether blocking IL-1 signaling 
in the DH would attenuate heroin immunosuppression in order to address whether the effect 
seen in acquisition is due to the interruption of learning and memory or, alternatively, due to 
blocking the immune effects of heroin. Our results suggest that blocking IL-1 signaling in 
the DH does not interfere with acquisition of heroin conditioned immunosuppression by 
attenuating the immunosuppressive effects of heroin, but rather that IL-1 signaling may be 
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specifically involved in associative memory formation. However, this conclusion must be 
tempered with the fact that this experiment used a single injection of heroin and a single 
infusion of IL-1RA. It is unclear whether effects would be seen with multiple heroin and/or 
IL-1RA injections, as used in Experiment 1. This possibility will need to be investigated.
These results suggest that hippocampal IL-1 signaling is required for the acquisition of 
heroin conditioned immunosuppression, which is in agreement with previous reports 
demonstrating the importance of IL-1 signaling in other hippocampal-dependent forms of 
memory. However, results from the current study contrast with those of other studies 
investigating conditioned immunosuppression. In particular, Pacheco-López and colleagues 
(2007) showed that intracerebroventricular infusion of IL-1RA had no effect on the 
acquisition of taste-LPS associative memory (Pacheco-Lopez et al., 2007). We propose that 
this incongruence may be due to differences in the neural circuitry involved in the 
acquisition and expression of conditioned taste-immune vs. conditioned opiate-immune 
effects. It is unclear whether conditioned taste effects require the hippocampus in paradigms 
not employing a contextual component (Molero-Chamizo and Moron, 2015). In addition, 
prior studies demonstrated that the amygdala was important for the expression of heroin 
conditioned immunosuppression (Szczytkowski et al., 2011; Szczytkowski and Lysle, 2008, 
2010). Immune conditioning studies using cyclosporine A paired with a tastant, in contrast, 
have shown that this area was only required during acquisition of conditioned 
immunosuppression and not during expression (Pacheco-Lopez et al., 2005). These 
differences may be due to the use of different unconditioned and conditioned stimuli 
between taste and opiate conditioned immune effects, differential reliance on contextual 
memory, or differences in experimental design (e.g. targeting the basolateral aspect of the 
amygdala specifically versus the whole amygdalar complex). It was also demonstrated that 
the insular cortex and ventromedial hypothalamus were required throughout taste 
conditioned immmunosuppression or only during expression, respectively (Pacheco-Lopez 
et al., 2005), but it is unknown whether these regions are also required for contextual 
immune conditioning using heroin. Future studies should investigate these potential valuable 
distinctions.
Though it might be argued that repeated suppression of IL-1 signaling could disrupt heroin 
conditioned immunosuppression through non-specific compensatory mechanisms, the 
disruption of acquisition of this learned effect only when IL-1RA was administered into the 
DH before conditioning and not on days when conditioning did not take place, argues 
against this notion.
From the current results, it is still unclear whether hippocampal IL-1 signaling increases 
during the acquisition phase of heroin conditioned immunosuppression, or whether only 
basal levels are required for heroin context-immune associations to form. There is a plethora 
of experimental evidence that opioids can increase the activation of microglia and astrocytes 
through either glial μ-opioid receptor or toll-like receptor 4 (TLR4) activation, leading to the 
release of proinflammatory cytokines, including IL-1β (Coller and Hutchinson, 2012; 
Hutchinson et al., 2011; Motaghinejad et al., 2015; Wang et al., 2012). However, most of 
these studies were conducted in the spinal cord or under longer-term treatment with opioids 
than what was used in the present studies. Chronic morphine has been shown to elevate 
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astrocyte activation in the hippocampus (Song and Zhao, 2001), but again, it is unclear 
whether this would occur following five doses of heroin or whether this would lead to 
increased release of IL-1β. Stress-induced IL-1β expression was reduced in the dentate gyrus 
by morphine (Jones et al., 2015), indicating that opioids may have differential effects in 
different subregions of the hippocampus or that opioid action might depend on prior 
inflammatory states.
Neurons might also contribute to the release of IL-1β since both glia and neurons have been 
shown to release IL-1β in the brain (Goshen et al., 2007). TLR4 activation, being upstream 
of IL-1β release from glia, might also lead to opioid-mediated release of cytokines from 
neurons. Additionally, if heroin activates microglia in our paradigm, this may lead to 
potentiated release of IL-1β from neurons. Microglial activation following brain injury has 
been shown to upregulate TLR4 expression on hippocampal neurons (Li et al., 2015). 
Interestingly, this neuronal change in TLR4 expression was coupled with increased 
hippocampal excitability, especially in the dentate gyrus, and was increased or decreased by 
TLR4 agonists or antagonists, respectively. While this effect was not linked to the release of 
IL-1β directly, there is additional evidence indicating that a functional consequence of IL-1β 
release in the hippocampus could be modulation of neuronal excitability. IL-1β has been 
shown to cause changes in NMDA and AMPA receptor dynamics in the hippocampus, 
inhibit voltage dependent calcium channels in CA1, cause permanent inhibition of 
GABAergic signaling in dentate gyrus and CA3 neurons, and yet increase GABAergic 
signaling in CA1 [see (Schafers and Sorkin, 2008; Vezzani and Viviani, 2015)].
Also of note is the possibility of CB1-dependent regulation of opioid immune signaling. 
Heroin has been shown to produce CB1 signaling adaptations in the hippocampus following 
acquisition of self-administration (Fattore et al., 2007), indicating that opioids may modulate 
tonic expression of endocannabinoid signaling the hippocampus. There is evidence that 
basal expression of IL-1β in the hippocampus requires cannabinoid receptor, CB1 (Csolle 
and Sperlagh, 2011) therefore, there are multiple ways that opiates might modulate 
expression of IL-1β in the hippocampus so that IL-1β can contribute to heroin learning. The 
functional consequence of this IL-1β regulation may be subregion specific changes in 
neuronal excitability in the hippocampus. Future experiments should aim to explore IL-1β 
expression, glial activation, and the neuromodulatory functions of IL-1β in each of the 
subregions of the hippocampus within our heroin conditioning regimen.
It must be noted that our manipulation used the IL-1R1 endogenous receptor antagonist, 
IL-1RA. This receptor also binds to IL-1 alpha (IL-1α) and mediates its action, so the 
specificity of IL-1β in mediating the effects seen cannot be concluded definitively. Previous 
studies have shown that IL-1β signaling is required for the expression of heroin conditioned 
immunosuppression to a context through knockdown of IL-1β expression using IL-1β siRNA 
(Szczytkowski et al., 2013). For the current experiment, IL-1β siRNA was not temporally 
specific enough to target processes only during or shortly after each conditioning session. It 
has been shown in our experience to knockdown expression in vivo for at least 48 hours 
(Szczytkowski et al., 2013), and it has the potential to knockdown gene expression for up to 
four days (Dr. H. Y. Eminy Lee, Personal communication, 2010). IL-1RA, on the other hand, 
could have a much more acute effect, which is why it was used in the present study. Our 
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results seem to confirm that the effects of administering IL-1RA 24 hours apart were 
distinguishable.
To our knowledge, despite the fact that a preponderance of evidence suggests that opioid use 
can suppress the immune system in animal models, primates, and humans along with 
concerning evidence that this extends to clinical use, there has been no investigation as to the 
prevalence of opioid conditioned immunosuppression in therapeutic opioid use (Al-Hashimi 
et al., 2013; Brown et al., 2012; Sacerdote, 2006; Sacerdote et al., 2012; Santamaria et al., 
2010; Vallejo et al., 2004; Wu et al., 2015). Conditioned immunosuppression using other 
immunosuppressive drugs has been demonstrated in humans in the placebo literature 
(Albring et al., 2014; Albring et al., 2012; Goebel et al., 2002), so it is reasonable to 
hypothesize that opioid immune effects would be able to be conditioned in humans as well. 
This possibility should be explored in the future as it has the potential to greatly impact the 
clinical use of opioids in pain and cancer management. The current results suggest that 
therapeutic inhibition of IL-1 during the acquisition phase of associations between the 
immune system with opioids may help prevent usually benign stimuli from suppressing the 
immune system and may block increased infection risk. While more difficult to make use of 
this treatment in the case of heroin users, IL-1 inhibition could potentially alleviate 
immunosuppressive consequences of clinical opioid use. Further studies should be 
conducted to relate the current results to clinical application. The direct impact of 
hippocampal IL-1 blockade on pathogen resistance outcomes should be empirically tested. 
This study provides valuable insight into the neural mechanisms that contribute to heroin 
conditioned immunosuppression and characterizes IL-1 effects on an important measure of 
conditioned immunity.
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Highlights
• Acquisition of heroin conditioned immunosuppression requires 
hippocampal IL-1.
• IL-1 blockade did not affect immunosuppressive effects of a single dose of 
heroin.
• Hippocampal IL-1 signaling is likely involved in memory formation in this 
model.
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Figure 1. 
Experimental Design of Experiment 1. Following a surgery recovery period, rats were 
conditioned to associate a heroin injection with a distinct context. Rats in one group received 
an infusion of IL-1 receptor antagonist (IL-1RA) into the dorsal hippocampus (DH) 30 min 
before each of the five conditioning sessions (IL-1RA With Cond). Rats in another group 
received an IL-1RA infusion into the DH 24 h after the previous conditioning session, on 
non-conditioning days (IL-1RA 24 h After Cond). Number of injections and injection 
manipulations were balanced between each group using saline infusions. Six days after the 
last infusion, half of the animals from each group were either re-exposed to the heroin-
paired context (CS) to test for conditioned immunosuppression or remained in the home-
cage for an equivalent period of time (HC). Immediately following, all animals were given a 
single injection of LPS and were sacrificed 6 hours later.
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Figure 2. 
Immune suppression to CS is attenuated by IL-1 signaling blockade before conditioning 
with heroin. IL-1 receptor antagonist (IL-1RA) administered just before each context-heroin 
pairing (left two bars), but not 24 h after on non-conditioning days (right two bars), 
attenuated suppression of splenic iNOS mRNA (A), splenic iNOS protein (B), and plasma 
nitrate/nitrite (C) upon re-exposure to the context (CS, light grey) compared to respective 
home cage controls receiving the same timing of IL-1RA treatment where conditioning was 
not evoked (HC, dark grey). Conditioned immune suppression to the CS was seen only in 
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groups that received IL-1RA on non-conditioning days. (*, significantly different relative to 
respective control group; Tukey’s HSD, p < 0.05).
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Figure 3. 
Experimental Design of Experiment 2. Following a surgery recovery period, rats received an 
infusion of IL-1 receptor antagonist (IL-1RA) or saline (Sal) into the dorsal hippocampus 
(DH) 30 min before a single subcutaneous injection of saline (Sal) or heroin (Her). One hour 
later, all animals were given a single injection of LPS and were sacrificed 6 hours later.
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Figure 4. 
Immune suppression to heroin is not attenuated by IL-1 signaling blockade. IL-1 receptor 
antagonist (IL-1RA) administered 30 min before (light grey bars) an injection of heroin did 
not attenuate suppression of splenic iNOS mRNA (A), splenic iNOS protein (B) and plasma 
nitrate/nitrite (C). (*, significantly different; Tukey’s HSD, p < 0.05).
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